Eli Lilly's shares saw a notable increase of over 5% as the company engages in talks with the Trump administration aimed at enhancing patient access and reducing drug prices. While this marks a positive shift, the stock remains down 2% year-to-date and is trading 18.2% below its 52-week high. Eli Lilly's recent acquisition of Versanis and the robust profitability outlook further position the company strongly in a competitive market, especially in the obesity and diabetes sectors.
“Eli Lilly · closed · up · more than +5%”
“Eli Lilly and other major drugmakers · are in · active discussions · with the Trump administration”
“Eli Lilly · is in discussions with · the Trump administration · to expand patient access”
“Eli Lilly · closed up · more than +5%”
“Eli Lilly · closed up by · +5%”
“Eli Lilly · is in talks with · the Trump administration · to provide discounted drugs to consumers”
“Eli Lilly · is discussing · patient access and affordability · with the administration”
“Eli Lilly · shares jumped · percentage · 5.5%”
“Eli Lilly · shares closed at · price · $762.38”
“Eli Lilly · is down · percentage since the beginning of the year · 2%”
“Eli Lilly · is trading · percentage below its 52-week high · 18.2%”
“Eli Lilly and Company · is among · the 10 Best Money Making Stocks to Invest In · true”
